Ameritas Investment Partners’s Stemline Therapeutics, Inc. STML Stock Holding History

Ameritas Investment Partners’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,938	Closed	-$19K	–	3226
2020 Q1	$19K	Hold	3,938	–	–	﹤0.01%	2224
2019 Q4	$42K	Buy	3,938 +785	+25%	+$7.79K	﹤0.01%	2023
2019 Q3	$33K	Hold	3,153	–	–	﹤0.01%	2128
2019 Q2	$48K	Hold	3,153	–	–	﹤0.01%	1942
2019 Q1	$41K	Buy	3,153 +1,223	+63%	+$13.8K	﹤0.01%	2005
2018 Q4	$18K	Hold	1,930	–	–	﹤0.01%	2418
2018 Q3	$32K	Hold	1,930	–	–	﹤0.01%	2258
2018 Q2	$31K	Hold	1,930	–	–	﹤0.01%	2271
2018 Q1	$30K	Hold	1,930	–	–	﹤0.01%	2217
2017 Q4	$30K	Buy	1,930 +617	+47%	+$8.25K	﹤0.01%	2231
2017 Q3	$11K	Hold	1,313	–	–	﹤0.01%	2749
2017 Q2	$12K	Hold	1,313	–	–	﹤0.01%	2769
2017 Q1	$11K	Buy	+1,313	New	+$12K	﹤0.01%	2675

Ameritas Investment Partners's STML Position: Q2 2020 in Review

Ameritas Investment Partners sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 3,938 shares — an estimated $19K sold.

Ameritas Investment Partners first reported a position in STML in Q1 2017 and held it in 13 quarters. The position peaked at $48K in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Ameritas Investment Partners reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Ameritas Investment Partners sold 3,938 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $19K.
Ameritas Investment Partners first reported a position in Stemline Therapeutics, Inc. in Q1 2017 and held it in 13 quarters.
Ameritas Investment Partners's Stemline Therapeutics, Inc. position peaked at $48K in Q2 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Ameritas Investment Partners's 13F filing for Q2 2020, filed 5 Aug 2020.